Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer

References

• Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873(1):188314. doi:10.1016/j.bbcan.2019.188314
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastro Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Makary MS, Ramsell S, Miller E, Beal EW, Dowell JD. Hepatocellular carcinoma locoregional therapies: outcomes and future horizons. World J Gastroenterol. 2021;27(43):7462–7479. doi:10.3748/wjg.v27.i43.7462
   PubMed Web of Science ®Google Scholar
• Patel K, Lamm R, Altshuler P, Dang H, Shah AP. Hepatocellular carcinoma-the influence of immunoanatomy and the role of immunotherapy. Int J Mol Sci. 2020;21(18):6757. doi:10.3390/ijms21186757
   PubMed Web of Science ®Google Scholar
• Tsilimigras DI, Bagante F, Sahara K, et al. Prognosis after resection of barcelona clinic liver cancer (BCLC) Stage 0, A, and B hepatocellular carcinoma: a comprehensive assessment of the current BCLC classification. Ann Surg Oncol. 2019;26(11):3693–3700. doi:10.1245/s10434-019-07580-9
   PubMed Web of Science ®Google Scholar
• Liang L, Xing H, Zhang H, et al. Surgical resection versus transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford). 2018;20(2):110–119. doi:10.1016/j.hpb.2017.10.004
   PubMed Web of Science ®Google Scholar
• Gao Y, Lyu L, Feng Y, Li F, Hu Y. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): perspectives from patents. Int J Med Sci. 2021;18(14):3066–3081. doi:10.7150/ijms.59930
   PubMed Web of Science ®Google Scholar
• Rommasi F, Esfandiari N. Liposomal nanomedicine: applications for drug delivery in cancer therapy. Nanoscale Res Lett. 2021;16(1):95. doi:10.1186/s11671-021-03553-8
   PubMed Web of Science ®Google Scholar
• Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1(3):297–315.
   PubMed Web of Science ®Google Scholar
• Wang J, Gong J, Wei Z. Strategies for liposome drug delivery systems to improve tumor treatment efficacy. AAPS PharmSciTech. 2021;23(1):27. doi:10.1208/s12249-021-02179-4
   PubMed Web of Science ®Google Scholar
• Nakhaei P, Margiana R, Bokov DO, et al. Liposomes: structure, biomedical applications, and stability parameters with emphasis on cholesterol. Front Bioeng Biotechnol. 2021;9:705886. doi:10.3389/fbioe.2021.705886
   PubMed Web of Science ®Google Scholar
• Yan W, Leung SSY, To KKW. Updates on the use of liposomes for active tumor targeting in cancer therapy. Nanomedicine. 2020;15(3):303–318. doi:10.2217/nnm-2019-0308
   PubMed Web of Science ®Google Scholar
• Koirala N, Das D, Fayazzadeh E, et al. Folic acid conjugated polymeric drug delivery vehicle for targeted cancer detection in hepatocellular carcinoma. J Biomed Mater Res A. 2019;107(11):2522–2535. doi:10.1002/jbm.a.36758
   PubMed Web of Science ®Google Scholar
• Pittala S, Krelin Y, Shoshan-Barmatz V. Targeting liver cancer and associated pathologies in mice with a mitochondrial VDAC1-based peptide. Neoplasia. 2018;20(6):594–609. doi:10.1016/j.neo.2018.02.012
   PubMed Web of Science ®Google Scholar
• D’Souza AA, Devarajan PV. Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications. J Control Release. 2015;203:126–139. doi:10.1016/j.jconrel.2015.02.022
   PubMed Web of Science ®Google Scholar
• Arranja AG, Pathak V, Lammers T, Shi Y. Tumor-targeted nanomedicines for cancer theranostics. Pharmacol Res. 2017;115:87–95. doi:10.1016/j.phrs.2016.11.014
   PubMed Web of Science ®Google Scholar
• Kalyane D, Raval N, Maheshwari R, Tambe V, Kalia K, Tekade RK. Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater Sci Eng C Mater Biol Appl. 2019;98:1252–1276. doi:10.1016/j.msec.2019.01.066
   PubMed Web of Science ®Google Scholar
• Lee Y, Thompson DH. Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(5). doi:10.1002/wnan.1450
   Web of Science ®Google Scholar
• Mokdad AA, Singal AG, Yopp AC. Jama Patient Page. Treatment of liver cancer. JAMA. 2016;315(1):100. doi:10.1001/jama.2015.15431
   PubMedGoogle Scholar
• Bray F, Ren J-S, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133–1145. doi:10.1002/ijc.27711
   PubMed Web of Science ®Google Scholar
• Hernández-Aquino E, Muriel P. Beneficial effects of naringenin in liver diseases: molecular mechanisms. World J Gastroenterol. 2018;24(16):1679–1707. doi:10.3748/wjg.v24.i16.1679
   PubMed Web of Science ®Google Scholar
• Ho SY, Hsu CY, Liu PH, et al. Survival of patients with hepatocellular carcinoma in renal insufficiency: prognostic role of albumin-bilirubin grade. Cancers (Basel). 2020;12(5):1130. doi:10.3390/cancers12051130
   PubMed Web of Science ®Google Scholar
• Lee EC, Kim SH, Park H, Lee SD, Lee SA, Park SJ. Survival analysis after liver resection for hepatocellular carcinoma: a consecutive cohort of 1002 patients. J Gastroenterol Hepatol. 2017;32(5):1055–1063. doi:10.1111/jgh.13632
   PubMed Web of Science ®Google Scholar
• Cao Y, Xu L, Kuang Y, Xiong D, Pei R. Gadolinium-based nanoscale MRI contrast agents for tumor imaging. J Mater Chem B. 2017;5(19):3431–3461. doi:10.1039/c7tb00382j
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146(7):1691–700. e3. doi:10.1053/j.gastro.2014.02.032
   PubMed Web of Science ®Google Scholar
• Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD011650. doi:10.1002/14651858.CD011650.pub2
   PubMed Web of Science ®Google Scholar
• Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243(2):229–235. doi:10.1097/01.sla.0000197706.21803.a1
   PubMed Web of Science ®Google Scholar
• Vivarelli M, Cucchetti A, La Barba G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg. 2008;248(5):857–862. doi:10.1097/SLA.0b013e3181896278
   PubMed Web of Science ®Google Scholar
• Ko KL, Mak LY, Cheung KS, Yuen MF. Hepatocellular carcinoma: recent advances and emerging medical therapies. F1000Res. 2020;9:F1000 Faculty Rev–620. doi:10.12688/f1000research.24543.1
   PubMedGoogle Scholar
• Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol. 2009;10(5):425–434. doi:10.3348/kjr.2009.10.5.425
   PubMed Web of Science ®Google Scholar
• Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv238–iv255. doi:10.1093/annonc/mdy308
   PubMed Web of Science ®Google Scholar
• Villanueva A, Longo DL. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra1713263
   PubMed Web of Science ®Google Scholar
• Wang T, Suita Y, Miriyala S, Dean J, Tapinos N, Shen J. Advances in lipid-based nanoparticles for cancer chemoimmunotherapy. Pharmaceutics. 2021;13(4):520. doi:10.3390/pharmaceutics13040520
   PubMed Web of Science ®Google Scholar
• Chan C, Du S, Dong YZ, Cheng XL. Computational and experimental approaches to investigate lipid nanoparticles as drug and gene delivery systems. Curr Top Med Chem. 2021;21(2):92–114. doi:10.2174/1568026620666201126162945
   PubMed Web of Science ®Google Scholar
• Duan L, Yang L, Jin J, et al. Micro/nano-bubble-assisted ultrasound to enhance the EPR effect and potential theranostic applications. Theranostics. 2020;10(2):462–483. doi:10.7150/thno.37593
   PubMed Web of Science ®Google Scholar
• Fang J, Islam W, Maeda H. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Adv Drug Deliv Rev. 2020;157:142–160. doi:10.1016/j.addr.2020.06.005
   PubMed Web of Science ®Google Scholar
• Kiaie SH, Mojarad-Jabali S, Khaleseh F, et al. Axial pharmaceutical properties of liposome in cancer therapy: recent advances and perspectives. Int J Pharm. 2020;581:119269. doi:10.1016/j.ijpharm.2020.119269
   PubMed Web of Science ®Google Scholar
• Li RR, Kowalski PS, Morselt HWM, et al. Endothelium-targeted delivery of dexamethasone by anti-VCAM-1 SAINT-O-Somes in mouse endotoxemia. PLoS One. 2018;13(5):e0196976. doi:10.1371/journal.pone.0196976
   PubMed Web of Science ®Google Scholar
• Li XC, Diao WB, Xue HT, et al. Improved efficacy of doxorubicin delivery by a novel dual-ligand-modified liposome in hepatocellular carcinoma. Cancer Lett. 2020;489:163–173. doi:10.1016/j.canlet.2020.06.017
   PubMed Web of Science ®Google Scholar
• Chen JD, Jiang H, Wu Y, Li YD, Gao Y. A novel glycyrrhetinic acid-modified oxaliplatin liposome for liver-targeting and in vitro/vivo evaluation. Drug Des Dev Ther. 2015;9:2265–2275. doi:10.2147/Dddt.S81722
   PubMed Web of Science ®Google Scholar
• Lian B, Wei H, Pan RY, et al. Galactose modified liposomes for effective co-delivery of doxorubicin and combretastatin A4. Int J Nanomed. 2021;16:457–467. doi:10.2147/Ijn.S283793
   PubMed Web of Science ®Google Scholar
• Chen XY, Hu XX, Hu JJ, Qiu ZP, Yuan M, Zheng GH. Celastrol-loaded galactosylated liposomes effectively inhibit AKT/c-met-triggered rapid hepatocarcinogenesis in mice. Mol Pharm. 2020;17(3):738–747. doi:10.1021/acs.molpharmaceut.9b00428
   PubMed Web of Science ®Google Scholar
• Farinha D, de Lima MCP, Faneca H. Specific and efficient gene delivery mediated by an asialofetuin-associated nanosystem. Int J Pharm. 2014;473(1–2):366–374. doi:10.1016/j.ijpharm.2014.07.019
   PubMed Web of Science ®Google Scholar
• Bansal D, Yadav K, Pandey V, Ganeshpurkar A, Agnihotri A, Dubey N. Lactobionic acid coupled liposomes: an innovative strategy for targeting hepatocellular carcinoma. Drug Deliv. 2016;23(1):140–146. doi:10.3109/10717544.2014.907373
   PubMed Web of Science ®Google Scholar
• Oh HR, Jo HY, Park JS, et al. Galactosylated liposomes for targeted co-delivery of doxorubicin/vimentin siRNA to hepatocellular carcinoma. Nanomaterials (Basel). 2016;6(8):141. doi:10.3390/nano6080141
   PubMedGoogle Scholar
• Pireddu R, Pibiri M, Valenti D, et al. A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine. Int J Pharm. 2018;537(1–2):257–267. doi:10.1016/j.ijpharm.2017.12.048
   PubMed Web of Science ®Google Scholar
• Sun D, Tan SY, Xiong YL, et al. MicroRNA biogenesis is enhanced by liposome-encapsulated Pin1 inhibitor in hepatocellular carcinoma. Theranostics. 2019;9(16):4704–4716. doi:10.7150/thno.34588
   PubMed Web of Science ®Google Scholar
• Liu MC, Liu L, Wang XR, et al. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo. Int J Nanomed. 2016;11:1395–1412. doi:10.2147/Ijn.S96862
   PubMed Web of Science ®Google Scholar
• Zhang WD, Peng FQ, Zhou TT, et al. Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes. Int J Nanomed. 2015;10:4825–4836. doi:10.2147/Ijn.S79598
   PubMed Web of Science ®Google Scholar
• Wei YH, Gu XL, Cheng L, Meng FH, Storm G, Zhong ZY. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo. Acta Biomater. 2019;92:196–204. doi:10.1016/j.actbio.2019.05.034
   PubMed Web of Science ®Google Scholar
• Alanazi SA, Harisa GI, Badran MM, et al. Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition. Bioengineered. 2021;12(1):914–926. doi:10.1080/21655979.2021.1896202
   PubMed Web of Science ®Google Scholar
• Fang Y, Yang WJ, Cheng L, Meng FH, Zhang J, Zhong ZY. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo. Acta Biomater. 2017;64:323–333. doi:10.1016/j.actbio.2017.10.013
   PubMed Web of Science ®Google Scholar
• Gao J, Chen HW, Yu YS, et al. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of Adriamycin and ribonucleotide reductase M2 siRNA. Biomaterials. 2013;34(38):10084–10098. doi:10.1016/j.biomaterials.2013.08.088
   PubMed Web of Science ®Google Scholar
• Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin. 2004;130(7):417–422. doi:10.1007/s00432-004-0552-0
   PubMed Web of Science ®Google Scholar
• Ren Y, He S, Huttad L, et al. An NIR-II/MR dual modal nanoprobe for liver cancer imaging. Nanoscale. 2020;12(21):11510–11517. doi:10.1039/d0nr00075b
   PubMed Web of Science ®Google Scholar
• Wallnofer EA, Thurner GC, Kremser C, et al. Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles. Histochem Cell Biol. 2021;155(1):19–73. doi:10.1007/s00418-020-01919-0
   PubMed Web of Science ®Google Scholar
• Šimečková P, Hubatka F, Kotouček J, et al. Gadolinium labelled nanoliposomes as the platform for MRI theranostics: in vitro safety study in liver cells and macrophages. Sci Rep. 2020;10(1):4780. doi:10.1038/s41598-020-60284-z
   PubMed Web of Science ®Google Scholar
• Fouillet X, Tournier H, Khan H, et al. Enhancement of computed tomography liver contrast using iomeprol-containing liposomes and detection of small liver tumors in rats. Acad Radiol. 1995;2(7):576–583. doi:10.1016/s1076-6332(05)80118-7
   PubMed Web of Science ®Google Scholar
• Lee SY, Jeon SI, Jung S, Chung IJ, Ahn CH. Targeted multimodal imaging modalities. Adv Drug Deliv Rev. 2014;76:60–78. doi:10.1016/j.addr.2014.07.009
   PubMed Web of Science ®Google Scholar
• Lamichhane N, Dewkar GK, Sundaresan G, Mahon RN, Zweit J. [(18)F]-Fluorinated Carboplatin and [(111)In]-liposome for image-guided drug delivery. Int J Mol Sci. 2017;18(5):1079. doi:10.3390/ijms18051079
   PubMed Web of Science ®Google Scholar
• Guan T, Shang W, Li H, et al. From detection to resection: photoacoustic tomography and surgery guidance with indocyanine green loaded gold Nanorod@liposome core-shell nanoparticles in liver cancer. Bioconjug Chem. 2017;28(4):1221–1228. doi:10.1021/acs.bioconjchem.7b00065
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen C, Luo Y, et al. Experimental study of tumor therapy mediated by multimodal imaging based on a biological targeting synergistic agent. Int J Nanomedicine. 2020;15:1871–1888. doi:10.2147/ijn.S238398
   PubMed Web of Science ®Google Scholar
• Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25(4):198–213. doi:10.1016/j.tcb.2014.11.006
   PubMed Web of Science ®Google Scholar
• Li YL, Zhu XM, Liang H, Orvig C, Chen ZF. Recent advances in asialoglycoprotein receptor and glycyrrhetinic acid receptor-mediated and/or pH-responsive hepatocellular carcinoma-targeted drug delivery. Curr Med Chem. 2021;28(8):1508–1534. doi:10.2174/0929867327666200505085756
   PubMed Web of Science ®Google Scholar
• Cai Y, Xu Y, Chan HF, Fang X, He C, Chen M. Glycyrrhetinic acid mediated drug delivery carriers for hepatocellular carcinoma therapy. Mol Pharm. 2016;13(3):699–709. doi:10.1021/acs.molpharmaceut.5b00677
   PubMed Web of Science ®Google Scholar
• Kindrat I, Tryndyak V, de Conti A, et al. MicroRNA-152-mediated dysregulation of hepatic transferrin receptor 1 in liver carcinogenesis. Oncotarget. 2016;7(2):1276–1287. doi:10.18632/oncotarget.6004
   PubMedGoogle Scholar
• Joo I, Kim H, Lee JM. Cancer stem cells in primary liver cancers: pathological concepts and imaging findings. Korean J Radiol. 2015;16(1):50–68. doi:10.3348/kjr.2015.16.1.50
   PubMed Web of Science ®Google Scholar
• Dou L, Shi X, He X, Gao Y. Macrophage phenotype and function in liver disorder. Front Immunol. 2019;10:3112. doi:10.3389/fimmu.2019.03112
   PubMed Web of Science ®Google Scholar
• You Q, Cheng L, Kedl RM, Ju C. Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. Hepatology. 2008;48(3):978–990. doi:10.1002/hep.22395
   PubMed Web of Science ®Google Scholar
• Ding T, Xu J, Wang F, et al. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol. 2009;40(3):381–389. doi:10.1016/j.humpath.2008.08.011
   PubMed Web of Science ®Google Scholar
• Li XG, Yao WB, Yuan Y, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017;66(1):157–167. doi:10.1136/gutjnl-2015-310514
   PubMed Web of Science ®Google Scholar
• Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36. doi:10.1016/j.ctrv.2018.11.002
   PubMed Web of Science ®Google Scholar
• Li T, Yu P, Chen Y, et al. N-acetylgalactosamine-decorated nanoliposomes for targeted delivery of paclitaxel to hepatocellular carcinoma. Eur J Med Chem. 2021;222:113605. doi:10.1016/j.ejmech.2021.113605
   PubMed Web of Science ®Google Scholar
• Zhang J, Hu XX, Zheng GH, Yao H, Liang HL. In vitro and in vivo antitumor effects of lupeol-loaded galactosylated liposomes. Drug Deliv. 2021;28(1):709–718. doi:10.1080/10717544.2021.1905749
   PubMed Web of Science ®Google Scholar
• Wang S, Xu H, Xu J, et al. Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid. AAPS PharmSciTech. 2010;11(2):870–877. doi:10.1208/s12249-010-9450-8
   PubMed Web of Science ®Google Scholar
• Meier A, Mehrle S, Weiss TS, Mier W, Urban S. Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatology. 2013;58(1):31–42. doi:10.1002/hep.26181
   PubMed Web of Science ®Google Scholar
• Yan H, Zhong GC, Xu GW, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012;1:e00049. doi:10.7554/eLife.00049
   PubMed Web of Science ®Google Scholar
• Blank A, Markert C, Hohmann N, et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol. 2016;65(3):483–489. doi:10.1016/j.jhep.2016.04.013
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang Q, Peng Q, et al. Hepatitis B virus preS1-derived lipopeptide functionalized liposomes for targeting of hepatic cells. Biomaterials. 2014;35(23):6130–6141. doi:10.1016/j.biomaterials.2014.04.037
   PubMed Web of Science ®Google Scholar
• Wisse E, Jacobs F, Topal B, Frederik P, De Geest B. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther. 2008;15(17):1193–1199. doi:10.1038/gt.2008.60
   PubMed Web of Science ®Google Scholar
• Witzigmann D, Uhl P, Sieber S, et al. Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptide. Elife. 2019;8:e42276. doi:10.7554/eLife.42276
   PubMed Web of Science ®Google Scholar
• An Y, Yang R, Wang X, et al. Facile assembly of thermosensitive liposomes for active targeting imaging and synergetic chemo-/magnetic hyperthermia therapy. Front Bioeng Biotechnol. 2021;9:691091. doi:10.3389/fbioe.2021.691091
   PubMed Web of Science ®Google Scholar
• Salzano G, Marra M, Porru M, et al. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. Int J Pharm. 2011;403(1–2):292–297. doi:10.1016/j.ijpharm.2010.10.046
   PubMed Web of Science ®Google Scholar
• Li P, He K, Li J, Liu Z, Gong J. The role of Kupffer cells in hepatic diseases. Mol Immunol. 2017;85:222–229. doi:10.1016/j.molimm.2017.02.018
   PubMed Web of Science ®Google Scholar
• Böttcher JP, Knolle PA, Stabenow D. Mechanisms balancing tolerance and immunity in the liver. Dig Dis. 2011;29(4):384–390. doi:10.1159/000329801
   PubMed Web of Science ®Google Scholar
• Zhao QH, Zhang XS, Wu K, et al. Preparation of Zoledronate liposome and its impact on apoptosis of Kupffer cells in rat liver. Acta Cir Bras. 2018;33(12):1052–1060. doi:10.1590/s0102-865020180120000002
   PubMed Web of Science ®Google Scholar
• Jin Z, Yi X, Yang J, Zhou M, Wu P, Yan G. Liposome-coated arsenic-manganese complex for magnetic resonance imaging-guided synergistic therapy against carcinoma. Int J Nanomedicine. 2021;16:3775–3788. doi:10.2147/ijn.S313962
   PubMed Web of Science ®Google Scholar
• Zhao Z, Wang X, Zhang Z, et al. Real-time monitoring of arsenic trioxide release and delivery by activatable T(1) imaging. ACS Nano. 2015;9(3):2749–2759. doi:10.1021/nn506640h
   PubMed Web of Science ®Google Scholar
• Zhang K, Lin H, Mao J, et al. An extracellular pH-driven targeted multifunctional manganese arsenite delivery system for tumor imaging and therapy. Biomater Sci. 2019;7(6):2480–2490. doi:10.1039/c9bm00216b
   PubMed Web of Science ®Google Scholar
• Witzigmann D, Kulkarni JA, Leung J, Chen S, Cullis PR, Van Der Meel R. Lipid nanoparticle technology for therapeutic gene regulation in the liver. Adv Drug Deliv Rev. 2020;159:344–363. doi:10.1016/j.addr.2020.06.026
   PubMed Web of Science ®Google Scholar
• Jiménez Calvente C, Sehgal A, Popov Y, et al. Specific hepatic delivery of procollagen α1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis. Hepatology. 2015;62(4):1285–1297. doi:10.1002/hep.27936
   PubMed Web of Science ®Google Scholar
• Entzian K, Aigner A. Drug delivery by ultrasound-responsive nanocarriers for cancer treatment. Pharmaceutics. 2021;13(8):1135. doi:10.3390/pharmaceutics13081135
   PubMed Web of Science ®Google Scholar
• Ho W, Gao M, Li F, Li Z, Zhang XQ, Xu X. Next-generation vaccines: nanoparticle-mediated DNA and mRNA delivery. Adv Healthc Mater. 2021;10(8):e2001812. doi:10.1002/adhm.202001812
   PubMed Web of Science ®Google Scholar
• Kulkarni JA, Witzigmann D, Chen S, Cullis PR, van der Meel R. Lipid nanoparticle technology for clinical translation of siRNA therapeutics. Acc Chem Res. 2019;52(9):2435–2444. doi:10.1021/acs.accounts.9b00368
   PubMed Web of Science ®Google Scholar
• Watanabe T, Umehara T, Yasui F, et al. Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome. J Hepatol. 2007;47(6):744–750. doi:10.1016/j.jhep.2007.06.015
   PubMed Web of Science ®Google Scholar
• Kullberg M, McCarthy R, Anchordoquy TJ. Systemic tumor-specific gene delivery. J Control Release. 2013;172(3):730–736. doi:10.1016/j.jconrel.2013.08.300
   PubMed Web of Science ®Google Scholar
• Wang K, Shang F, Chen D, et al. Protein liposomes-mediated targeted acetylcholinesterase gene delivery for effective liver cancer therapy. J Nanobiotechnology. 2021;19(1):31. doi:10.1186/s12951-021-00777-9
   PubMed Web of Science ®Google Scholar
• Yanez Arteta M, Kjellman T, Bartesaghi S, et al. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Proc Natl Acad Sci U S A. 2018;115(15):E3351–E3360. doi:10.1073/pnas.1720542115
   PubMed Web of Science ®Google Scholar
• Miao L, Lin J, Huang Y, et al. Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver. Nat Commun. 2020;11(1):2424. doi:10.1038/s41467-020-16248-y
   PubMed Web of Science ®Google Scholar
• Fu LH, Hu YR, Qi C, et al. Biodegradable manganese-doped calcium phosphate nanotheranostics for traceable cascade reaction-enhanced anti-tumor therapy. ACS Nano. 2019;13(12):13985–13994. doi:10.1021/acsnano.9b05836
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Kuriyama S, Yoshii J, et al. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology. 1998;28(6):1489–1496. doi:10.1002/hep.510280607
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Kuriyama S, Hicklin DJ, et al. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology. 1999;30(5):1179–1186. doi:10.1002/hep.510300509
   PubMed Web of Science ®Google Scholar
• Wang M, Zhao X, Zhu D, et al. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment. J Exp Clin Cancer Res. 2017;36(1):60. doi:10.1186/s13046-017-0533-1
   PubMed Web of Science ®Google Scholar
• Torimura T, Ueno T, Sata M. Liposome-mediated gene transfer of K1-5 suppresses tumor development and improves the prognosis of hepatocellular carcinoma in mice. Med Mol Morphol. 2006;39(2):72–78. doi:10.1007/s00795-006-0319-6
   PubMed Web of Science ®Google Scholar
• Dou L, Ono Y, Chen YF, Thomson AW, Chen XP. Hepatic dendritic cells, the tolerogenic liver environment, and liver disease. Semin Liver Dis. 2018;38(2):170–180. doi:10.1055/s-0038-1646949
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Mauriello A, Cavalluzzo B, Petrizzo A, Tagliamonte M. Immunotherapy in hepatocellular carcinoma. Ann Hepatol. 2019;18(2):291–297. doi:10.1016/j.aohep.2019.04.003
   PubMed Web of Science ®Google Scholar
• Li G, Liu D, Kimchi ET, et al. Nanoliposome C6-ceramide increases the anti-tumor immune response and slows growth of liver tumors in mice. Gastroenterology. 2018;154(4):1024–1036.e9. doi:10.1053/j.gastro.2017.10.050
   PubMed Web of Science ®Google Scholar
• Iwama T, Uchida T, Sawada Y, et al. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice. Biochem Biophys Res Commun. 2016;469(1):138–143. doi:10.1016/j.bbrc.2015.11.084
   PubMed Web of Science ®Google Scholar
• Tehrani Fateh S, Moradi L, Kohan E, Hamblin MR, Shiralizadeh Dezfuli A. Comprehensive review on ultrasound-responsive theranostic nanomaterials: mechanisms, structures and medical applications. Beilstein J Nanotechnol. 2021;12:808–862. doi:10.3762/bjnano.12.64
   PubMed Web of Science ®Google Scholar
• Zhu L, Altman MB, Laszlo A, et al. Ultrasound hyperthermia technology for radiosensitization. Ultrasound Med Biol. 2019;45(5):1025–1043. doi:10.1016/j.ultrasmedbio.2018.12.007
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhai W, Liu X, et al. Homotypic cell membrane-cloaked biomimetic nanocarrier for the accurate photothermal-chemotherapy treatment of recurrent hepatocellular carcinoma. J Nanobiotechnology. 2020;18(1):60. doi:10.1186/s12951-020-00617-2
   PubMed Web of Science ®Google Scholar
• Dou Y, Hynynen K, Allen C. To heat or not to heat: challenges with clinical translation of thermosensitive liposomes. J Control Release. 2017;249:63–73. doi:10.1016/j.jconrel.2017.01.025
   PubMed Web of Science ®Google Scholar
• Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000;60(5):1197–1201.
   PubMed Web of Science ®Google Scholar
• van den Bijgaart RJ, Eikelenboom DC, Hoogenboom M, Fütterer JJ, den Brok MH, Adema GJ. Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. Cancer Immunol Immunother. 2017;66(2):247–258. doi:10.1007/s00262-016-1891-9
   PubMed Web of Science ®Google Scholar
• Feng G, Hao L, Xu C, et al. High-intensity focused ultrasound-triggered nanoscale bubble-generating liposomes for efficient and safe tumor ablation under photoacoustic imaging monitoring. Int J Nanomedicine. 2017;12:4647–4659. doi:10.2147/ijn.S135391
   PubMed Web of Science ®Google Scholar
• Zhou Q, Wang K, Dou J, et al. Theranostic liposomes as nanodelivered chemotherapeutics enhanced the microwave ablation of hepatocellular carcinoma. Nanomedicine (Lond). 2019;14(16):2151–2167. doi:10.2217/nnm-2018-0424
   PubMed Web of Science ®Google Scholar
• Zhao P, Deng Y, Xiang G, Liu Y. Nanoparticle-assisted sonosensitizers and their biomedical applications. Int J Nanomedicine. 2021;16:4615–4630. doi:10.2147/ijn.S307885
   PubMed Web of Science ®Google Scholar
• Feng Y, Tian Z, Wan M. Bioeffects of low-intensity ultrasound in vitro: apoptosis, protein profile alteration, and potential molecular mechanism. J Ultrasound Med. 2010;29(6):963–974. doi:10.7863/jum.2010.29.6.963
   PubMed Web of Science ®Google Scholar
• Pellicori P, Platz E, Dauw J, et al. Ultrasound imaging of congestion in heart failure: examinations beyond the heart. Eur J Heart Fail. 2021;23(5):703–712. doi:10.1002/ejhf.2032
   PubMed Web of Science ®Google Scholar
• Tharkar P, Varanasi R, Wong WSF, Jin CT, Chrzanowski W. Nano-enhanced drug delivery and therapeutic ultrasound for cancer treatment and beyond. Front Bioeng Biotechnol. 2019;7:324. doi:10.3389/fbioe.2019.00324
   PubMed Web of Science ®Google Scholar
• Pang X, Xiao Q, Cheng Y, et al. Bacteria-responsive nanoliposomes as smart sonotheranostics for multidrug resistant bacterial infections. ACS Nano. 2019;13(2):2427–2438. doi:10.1021/acsnano.8b09336
   PubMed Web of Science ®Google Scholar
• Lin X, Song J, Chen X, Yang H. Ultrasound-activated sensitizers and applications. Angew Chem Int Ed Engl. 2020;59(34):14212–14233. doi:10.1002/anie.201906823
   PubMed Web of Science ®Google Scholar
• Son S, Kim JH, Wang X, et al. Multifunctional sonosensitizers in sonodynamic cancer therapy. Chem Soc Rev. 2020;49(11):3244–3261. doi:10.1039/c9cs00648f
   PubMed Web of Science ®Google Scholar
• Zhao H, Wu M, Zhu L, et al. Cell-penetrating peptide-modified targeted drug-loaded phase-transformation lipid nanoparticles combined with low-intensity focused ultrasound for precision theranostics against hepatocellular carcinoma. Theranostics. 2018;8(7):1892–1910. doi:10.7150/thno.22386
   PubMed Web of Science ®Google Scholar
• Klibanov AL, Shevchenko TI, Raju BI, Seip R, Chin CT. Ultrasound-triggered release of materials entrapped in microbubble-liposome constructs: a tool for targeted drug delivery. J Control Release. 2010;148(1):13–17. doi:10.1016/j.jconrel.2010.07.115
   PubMed Web of Science ®Google Scholar
• Costley D, Mc Ewan C, Fowley C, et al. Treating cancer with sonodynamic therapy: a review. Int J Hyperthermia. 2015;31(2):107–117. doi:10.3109/02656736.2014.992484
   PubMed Web of Science ®Google Scholar
• Nguyen AT, Wrenn SP. Acoustically active liposome-nanobubble complexes for enhanced ultrasonic imaging and ultrasound-triggered drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014;6(3):316–325. doi:10.1002/wnan.1255
   PubMed Web of Science ®Google Scholar
• Lin XH, Qiu Y, Song L, et al. Ultrasound activation of liposomes for enhanced ultrasound imaging and synergistic gas and sonodynamic cancer therapy. Nanoscale Horiz. 2019;4(3):747–756. doi:10.1039/c8nh00340h
   Web of Science ®Google Scholar
• Huang SL. Liposomes in ultrasonic drug and gene delivery. Adv Drug Deliv Rev. 2008;60(10):1167–1176. doi:10.1016/j.addr.2008.03.003
   PubMed Web of Science ®Google Scholar
• Egloff-Juras C, Bezdetnaya L, Dolivet G, Lassalle HP. NIR fluorescence-guided tumor surgery: new strategies for the use of indocyanine green. Int J Nanomedicine. 2019;14:7823–7838. doi:10.2147/ijn.S207486
   PubMed Web of Science ®Google Scholar
• Highley CB, Kim M, Lee D, Burdick JA. Near-infrared light triggered release of molecules from supramolecular hydrogel-nanorod composites. Nanomedicine (Lond). 2016;11(12):1579–1590. doi:10.2217/nnm-2016-0070
   PubMed Web of Science ®Google Scholar
• Hou YJ, Yang XX, Liu RQ, et al. Pathological mechanism of photodynamic therapy and photothermal therapy based on nanoparticles. Int J Nanomedicine. 2020;15:6827–6838. doi:10.2147/ijn.S269321
   PubMed Web of Science ®Google Scholar
• Kaneko J, Inagaki Y, Ishizawa T, et al. Photodynamic therapy for human hepatoma-cell-line tumors utilizing biliary excretion properties of indocyanine green. J Gastroenterol. 2014;49(1):110–116. doi:10.1007/s00535-013-0775-4
   PubMed Web of Science ®Google Scholar
• Reismann M, Bretschneider JC, von Plessen G, Simon U. Reversible photothermal melting of DNA in DNA-gold-nanoparticle networks. Small. 2008;4(5):607–610. doi:10.1002/smll.200701317
   PubMed Web of Science ®Google Scholar
• Li Z, Ye E, Lakshminarayanan R, Loh XJ. Recent advances of using hybrid nanocarriers in remotely controlled therapeutic delivery. Small. 2016;12(35):4782–4806. doi:10.1002/smll.201601129
   PubMed Web of Science ®Google Scholar
• Peng Y, Su Z, Wang X, et al. Near-infrared light laser-triggered release of doxorubicin and sorafenib from temperaturesensitive liposomes for synergistic therapy of hepatocellular carcinoma. J Biomed Nanotechnol. 2020;16(9):1381–1393. doi:10.1166/jbn.2020.2975
   PubMed Web of Science ®Google Scholar
• Mu W, Jiang D, Mu S, Liang S, Liu Y, Zhang N. Promoting early diagnosis and precise therapy of hepatocellular carcinoma by glypican-3-targeted synergistic chemo-photothermal theranostics. ACS Appl Mater Interfaces. 2019;11(26):23591–23604. doi:10.1021/acsami.9b05526
   PubMed Web of Science ®Google Scholar
• Reeßing F, Stuart MCA, Samplonius DF, et al. A light-responsive liposomal agent for MRI contrast enhancement and monitoring of cargo delivery. Chem Commun (Camb). 2019;55(72):10784–10787. doi:10.1039/c9cc05516a
   PubMed Web of Science ®Google Scholar
• Amiri M, Salavati-Niasari M, Akbari A. Magnetic nanocarriers: evolution of spinel ferrites for medical applications. Adv Colloid Interface Sci. 2019;265:29–44. doi:10.1016/j.cis.2019.01.003
   PubMed Web of Science ®Google Scholar
• Zhou P, Pan L, Deng G, et al. Fe@Fe3Ge2 nanoparticles for MR imaging-guided NIR-driven photodynamic therapy in vivo. J Mater Chem B. 2019;7(37):5661–5668. doi:10.1039/c9tb01173k
   PubMed Web of Science ®Google Scholar
• Lux F, Sancey L, Bianchi A, Crémillieux Y, Roux S, Tillement O. Gadolinium-based nanoparticles for theranostic MRI-radiosensitization. Nanomedicine (Lond). 2015;10(11):1801–1815. doi:10.2217/nnm.15.30
   PubMed Web of Science ®Google Scholar
• Xiao Y, Liu Y, Yang S, et al. Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment. Colloids Surf B Biointerfaces. 2016;141:83–92. doi:10.1016/j.colsurfb.2016.01.016
   PubMed Web of Science ®Google Scholar
• Chen J, Sheu AY, Li W, et al. Poly(lactide-co-glycolide) microspheres for MRI-monitored transcatheter delivery of sorafenib to liver tumors. J Control Release. 2014;184:10–17. doi:10.1016/j.jconrel.2014.04.008
   PubMed Web of Science ®Google Scholar
• Kumar S, Dutta J, Dutta PK, Koh J. A systematic study on chitosan-liposome based systems for biomedical applications. Int J Biol Macromol. 2020;160:470–481. doi:10.1016/j.ijbiomac.2020.05.192
   PubMed Web of Science ®Google Scholar
• Wang GW, Wu BH, Li QY, et al. Active transportation of liposome enhances tumor accumulation, penetration, and therapeutic efficacy. Small. 2020;16(44):e2004172. doi:10.1002/smll.202004172
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48. doi:10.1016/j.addr.2012.09.037
   PubMed Web of Science ®Google Scholar
• Zhou B, Li M, Xu X, et al. Integrin alpha2beta1 targeting DGEA-modified liposomal doxorubicin enhances antitumor efficacy against breast cancer. Mol Pharm. 2021;18(7):2634–2646. doi:10.1021/acs.molpharmaceut.1c00132
   PubMed Web of Science ®Google Scholar
• Bibi S, Lattmann E, Mohammed AR, Perrie Y. Trigger release liposome systems: local and remote controlled delivery? J Microencapsul. 2012;29(3):262–276. doi:10.3109/02652048.2011.646330
   PubMed Web of Science ®Google Scholar
• Lu RC, She B, Gao WT, et al. Positron-emission tomography for hepatocellular carcinoma: current status and future prospects. World J Gastroenterol. 2019;25(32):4682–4695. doi:10.3748/wjg.v25.i32.4682
   PubMed Web of Science ®Google Scholar